Bone-targeted imaging and radionuclide therapy in prostate cancer

Andrei H. Iagaru, Erik Mittra, Patrick M. Colletti, Hossein Jadvar

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Although selective metabolic and receptor-based molecular agents will surely be included in the future of prostate cancer diagnosis and therapy, currently available inorganic compounds-such as 18F-NaF for the diagnosis of bony disease and 223RaCl2 for the therapy of bone metastases-were recently shown to be superior to standard 99mTc-phosphonates for diagnosis and 153Sm-ethylenediaminetetramethylene phosphonate or 89SrCl2 for therapy. The advantages of 18F-NaF include improved lesion detection and, when used in combination with CT, improved diagnostic confidence and specificity. In addition to being the first approved α-emitter, 223RaCl2 is the first radiopharmaceutical to show an increase in overall survival, a decrease in skeletal events, palliation of bone pain, and a low profile of adverse reactions (which are mild and manageable). The management of metastatic bone disease with 223RaCl2 is uniquely satisfying, as patients can be monitored directly during their monthly treatment visits.

Original languageEnglish (US)
Pages (from-to)19S-24S
JournalJournal of Nuclear Medicine
Volume57
DOIs
StatePublished - Oct 1 2016
Externally publishedYes

Fingerprint

Radionuclide Imaging
Prostatic Neoplasms
Bone and Bones
Organophosphonates
Radiopharmaceuticals
Bone Diseases
Therapeutics
Neoplasm Metastasis
Pain
Survival

Keywords

  • Bone
  • Cancer
  • PET
  • PET/CT
  • Prostate
  • Radium

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Bone-targeted imaging and radionuclide therapy in prostate cancer. / Iagaru, Andrei H.; Mittra, Erik; Colletti, Patrick M.; Jadvar, Hossein.

In: Journal of Nuclear Medicine, Vol. 57, 01.10.2016, p. 19S-24S.

Research output: Contribution to journalArticle

Iagaru, Andrei H. ; Mittra, Erik ; Colletti, Patrick M. ; Jadvar, Hossein. / Bone-targeted imaging and radionuclide therapy in prostate cancer. In: Journal of Nuclear Medicine. 2016 ; Vol. 57. pp. 19S-24S.
@article{96ed7ecaadeb4ed1b1bb5a4f483074c4,
title = "Bone-targeted imaging and radionuclide therapy in prostate cancer",
abstract = "Although selective metabolic and receptor-based molecular agents will surely be included in the future of prostate cancer diagnosis and therapy, currently available inorganic compounds-such as 18F-NaF for the diagnosis of bony disease and 223RaCl2 for the therapy of bone metastases-were recently shown to be superior to standard 99mTc-phosphonates for diagnosis and 153Sm-ethylenediaminetetramethylene phosphonate or 89SrCl2 for therapy. The advantages of 18F-NaF include improved lesion detection and, when used in combination with CT, improved diagnostic confidence and specificity. In addition to being the first approved α-emitter, 223RaCl2 is the first radiopharmaceutical to show an increase in overall survival, a decrease in skeletal events, palliation of bone pain, and a low profile of adverse reactions (which are mild and manageable). The management of metastatic bone disease with 223RaCl2 is uniquely satisfying, as patients can be monitored directly during their monthly treatment visits.",
keywords = "Bone, Cancer, PET, PET/CT, Prostate, Radium",
author = "Iagaru, {Andrei H.} and Erik Mittra and Colletti, {Patrick M.} and Hossein Jadvar",
year = "2016",
month = "10",
day = "1",
doi = "10.2967/jnumed.115.170746",
language = "English (US)",
volume = "57",
pages = "19S--24S",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",

}

TY - JOUR

T1 - Bone-targeted imaging and radionuclide therapy in prostate cancer

AU - Iagaru, Andrei H.

AU - Mittra, Erik

AU - Colletti, Patrick M.

AU - Jadvar, Hossein

PY - 2016/10/1

Y1 - 2016/10/1

N2 - Although selective metabolic and receptor-based molecular agents will surely be included in the future of prostate cancer diagnosis and therapy, currently available inorganic compounds-such as 18F-NaF for the diagnosis of bony disease and 223RaCl2 for the therapy of bone metastases-were recently shown to be superior to standard 99mTc-phosphonates for diagnosis and 153Sm-ethylenediaminetetramethylene phosphonate or 89SrCl2 for therapy. The advantages of 18F-NaF include improved lesion detection and, when used in combination with CT, improved diagnostic confidence and specificity. In addition to being the first approved α-emitter, 223RaCl2 is the first radiopharmaceutical to show an increase in overall survival, a decrease in skeletal events, palliation of bone pain, and a low profile of adverse reactions (which are mild and manageable). The management of metastatic bone disease with 223RaCl2 is uniquely satisfying, as patients can be monitored directly during their monthly treatment visits.

AB - Although selective metabolic and receptor-based molecular agents will surely be included in the future of prostate cancer diagnosis and therapy, currently available inorganic compounds-such as 18F-NaF for the diagnosis of bony disease and 223RaCl2 for the therapy of bone metastases-were recently shown to be superior to standard 99mTc-phosphonates for diagnosis and 153Sm-ethylenediaminetetramethylene phosphonate or 89SrCl2 for therapy. The advantages of 18F-NaF include improved lesion detection and, when used in combination with CT, improved diagnostic confidence and specificity. In addition to being the first approved α-emitter, 223RaCl2 is the first radiopharmaceutical to show an increase in overall survival, a decrease in skeletal events, palliation of bone pain, and a low profile of adverse reactions (which are mild and manageable). The management of metastatic bone disease with 223RaCl2 is uniquely satisfying, as patients can be monitored directly during their monthly treatment visits.

KW - Bone

KW - Cancer

KW - PET

KW - PET/CT

KW - Prostate

KW - Radium

UR - http://www.scopus.com/inward/record.url?scp=84991387671&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84991387671&partnerID=8YFLogxK

U2 - 10.2967/jnumed.115.170746

DO - 10.2967/jnumed.115.170746

M3 - Article

C2 - 27694165

AN - SCOPUS:84991387671

VL - 57

SP - 19S-24S

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

SN - 0161-5505

ER -